MCID: ANL004
MIFTS: 41

Anal Canal Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Anal Canal Squamous Cell Carcinoma

MalaCards integrated aliases for Anal Canal Squamous Cell Carcinoma:

Name: Anal Canal Squamous Cell Carcinoma 12 15 70
Squamous Cell Carcinoma of the Anal Canal 58

Characteristics:

Orphanet epidemiological data:

58
squamous cell carcinoma of the anal canal
Inheritance: Not applicable;

Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:7177
NCIt 50 C7469
ICD10 via Orphanet 33 C21.1
Orphanet 58 ORPHA424019
UMLS 70 C1332262

Summaries for Anal Canal Squamous Cell Carcinoma

Disease Ontology : 12 An anal canal cancer that derives from epithelial squamous cells.

MalaCards based summary : Anal Canal Squamous Cell Carcinoma, also known as squamous cell carcinoma of the anal canal, is related to squamous cell carcinoma and anus cancer. An important gene associated with Anal Canal Squamous Cell Carcinoma is VEGFD (Vascular Endothelial Growth Factor D), and among its related pathways/superpathways are ERK Signaling and MAPK signaling pathway. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and lung, and related phenotypes are anal canal squamous cell carcinoma and abdominal pain

Related Diseases for Anal Canal Squamous Cell Carcinoma

Diseases related to Anal Canal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 10.7
2 anus cancer 10.5
3 neutropenia 10.5
4 squamous cell papilloma 10.4
5 toxic shock syndrome 10.4
6 papilloma 10.4
7 anal margin carcinoma 10.4
8 lymphopenia 10.4
9 esophageal cancer 10.2
10 kaposi sarcoma 10.2
11 lymphoma, hodgkin, classic 10.2
12 lymphoma, non-hodgkin, familial 10.2
13 erythema multiforme 10.2
14 colorectal adenocarcinoma 10.2
15 neurogenic bladder 10.2
16 anal margin squamous cell carcinoma 10.2
17 thrombocytopenia 10.2
18 neuroendocrine carcinoma 10.2
19 constipation 10.2
20 proctitis 10.2
21 peripheral nervous system disease 10.2
22 acquired immunodeficiency syndrome 10.2
23 neuropathy 10.2
24 hemorrhoid 10.2
25 internal hemorrhoid 10.2
26 bowen's disease 10.2
27 macrophage activation syndrome 10.2
28 rare tumor 10.2
29 anal canal carcinoma 10.2
30 colitis 10.2
31 rectum cancer 10.2
32 rectum adenocarcinoma 10.2
33 adenocarcinoma 10.2
34 anal squamous cell carcinoma 10.2
35 ulcerative colitis 10.2
36 in situ carcinoma 10.2
37 47,xyy 10.2
38 radiation induced cancer 10.2
39 malignant ciliary body melanoma 10.0 VEGFD FLT1
40 ciliary body cancer 10.0 VEGFD FLT1
41 twin-to-twin transfusion syndrome 10.0 VEGFD FLT1
42 kuhnt-junius degeneration 10.0 VEGFD FLT1
43 neovascular glaucoma 10.0 VEGFD FLT1
44 breast carcinoma in situ 9.8 KRT5 FLT1
45 sebaceous gland disease 9.7 PSENEN NCSTN
46 hidradenitis 9.7 PSENEN NCSTN
47 hidradenitis suppurativa 9.7 PSENEN NCSTN
48 breast ductal carcinoma 9.6 VEGFD KRT5
49 acne 9.6 PSENEN NCSTN
50 sweat gland disease 9.4 PSENEN NCSTN KRT5

Graphical network of the top 20 diseases related to Anal Canal Squamous Cell Carcinoma:



Diseases related to Anal Canal Squamous Cell Carcinoma

Symptoms & Phenotypes for Anal Canal Squamous Cell Carcinoma

Human phenotypes related to Anal Canal Squamous Cell Carcinoma:

58 31 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anal canal squamous cell carcinoma 58 31 obligate (100%) Obligate (100%) HP:0030438
2 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
3 papilloma 58 31 hallmark (90%) Very frequent (99-80%) HP:0012740
4 intestinal bleeding 58 31 hallmark (90%) Very frequent (99-80%) HP:0002584
5 lymphadenopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0002716
6 skin ulcer 58 31 occasional (7.5%) Occasional (29-5%) HP:0200042
7 rectal prolapse 58 31 occasional (7.5%) Occasional (29-5%) HP:0002035
8 neoplasm of the lung 58 31 occasional (7.5%) Occasional (29-5%) HP:0100526
9 neoplasm of the rectum 58 31 occasional (7.5%) Occasional (29-5%) HP:0100743
10 anal stenosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002025
11 neoplasm of the liver 58 31 occasional (7.5%) Occasional (29-5%) HP:0002896
12 neoplasm of the skeletal system 58 31 occasional (7.5%) Occasional (29-5%) HP:0010622

MGI Mouse Phenotypes related to Anal Canal Squamous Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.1 FLT1 KRT5 MAPK8IP1 NCSTN PSENEN VEGFD

Drugs & Therapeutics for Anal Canal Squamous Cell Carcinoma

Drugs for Anal Canal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
2
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
3 Antimitotic Agents Phase 3
4 Albumin-Bound Paclitaxel Phase 3
5 Tubulin Modulators Phase 3
6
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
7
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
8
Fluorouracil Approved Phase 2 51-21-8 3385
9
Ipilimumab Approved Phase 2 477202-00-9
10
nivolumab Approved Phase 2 946414-94-4
11
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
12
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
13 Immunosuppressive Agents Phase 2
14 Immunologic Factors Phase 2
15 Immunoglobulins Phase 2
16 Antibodies, Monoclonal Phase 2
17 Antibodies Phase 2
18 Antimetabolites Phase 2
19 Antineoplastic Agents, Immunological Phase 2
20 Antibiotics, Antitubercular Phase 2
21 Mitomycins Phase 2
22 Alkylating Agents Phase 2
23 Anti-Bacterial Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) Recruiting NCT04472429 Phase 3 carboplatin;paclitaxel;retifanlimab
2 A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
3 A Phase II Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
4 Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Feasibility Trial Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
5 A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal Recruiting NCT02314169 Phase 2
6 A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT) Recruiting NCT03870607 Phase 2
7 Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal Terminated NCT01843452 Phase 2 MITOMYCIN;CAPECITABINE
8 An Open Label, Randomized Phase II Study of BI 754091 Alone or in Combination With BI 836880 in Patients With Chemotherapy Resistant, Unresectable, Metastatic Squamous Cell Carcinoma of the Anal Canal Withdrawn NCT04499352 Phase 2 BI 754091;BI 836880

Search NIH Clinical Center for Anal Canal Squamous Cell Carcinoma

Genetic Tests for Anal Canal Squamous Cell Carcinoma

Anatomical Context for Anal Canal Squamous Cell Carcinoma

MalaCards organs/tissues related to Anal Canal Squamous Cell Carcinoma:

40
Lymph Node, Liver, Lung, Colon, Cervix, Breast, Prostate

Publications for Anal Canal Squamous Cell Carcinoma

Articles related to Anal Canal Squamous Cell Carcinoma:

(show top 50) (show all 282)
# Title Authors PMID Year
1
Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience. 61
33732911 2021
2
Assessing the Reliability and Positive Predictive Value of p16 as a Surrogate for Human Papillomavirus-Mediated E6/7 mRNA Expression in Squamous Cell Carcinoma of the Anal Canal. 61
33394778 2021
3
Chemotherapy use in early stage anal canal squamous cell carcinoma and its impact on long-term overall survival,,. 61
33711636 2021
4
Long-term bowel function patient-reported outcomes after successful chemoradiation for carcinoma of the anal canal. 61
33599113 2021
5
Outcomes of Squamous Cell Carcinoma Anal Canal treated with IMRT-VMAT-based Concurrent Chemoradiation: a Single Institutional Experience. 61
33400211 2021
6
[Surgery for Anal Canal Squamous Cell Carcinoma after Prostate Brachytherapy-A Case Report]. 61
33468822 2020
7
Ten years and counting: Survival in stage IV metastatic squamous cell carcinoma of anal canal following radical treatment. 61
33380684 2020
8
Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation. 61
32609585 2020
9
Chemoradiation-Related Lymphopenia and Its Association with Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. 61
32827337 2020
10
Squamous cell carcinoma of the rectum. 61
33130582 2020
11
Disease-Free Survival and Time to Complete Response After Definitive Chemoradiotherapy for Squamous-Cell Carcinoma of the Anus According to HIV Infection. 61
32389596 2020
12
Patterns of inguinal lymph node metastases in anal canal cancer and recommendations for elective clinical target volume (CTV) delineation. 61
32417349 2020
13
Case of Complete Remission After Volumetric Modulated Arc Therapy to Primary Tumor Alone in Locally Advanced Anal Canal Cancer With Active AIDS and Low CD4 Cell Count: Longest Survival in History? 61
32789041 2020
14
Relapsed refractory metastatic squamous cell cancer of anal canal in a patient with retroviral infection responding to cetuximab. 61
31684821 2020
15
Cystic Lymph Node Metastases From HPV-Associated Squamous Cell Carcinoma of the Anal Canal. 61
31866578 2020
16
Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure. 61
31809980 2020
17
A prospective, multi-centre trial of multi-parametric MRI as a biomarker in anal carcinoma. 61
31710944 2020
18
Difference in toxicity between HIV-positive and HIV-negative patients with squamous-cell cancer of the anal canal treated with concomitant radio-chemotherapy. 61
32175102 2020
19
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02). 61
31851776 2020
20
A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. 61
31350201 2019
21
Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. 61
31128146 2019
22
FDG-PET parameters predict for recurrence in anal cancer - results from a prospective, multicentre clinical trial. 61
31387597 2019
23
Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal. 61
31548820 2019
24
Trends in Radiation Dose and Technique For Anal Canal Squamous Cell Carcinoma. 61
31136369 2019
25
Importance of anal cytology and screening for anal dysplasia in individuals living with HIV with an emphasis on women. 61
31145557 2019
26
Local excision for patients with stage I anal canal squamous cell carcinoma can be curative. 61
31032082 2019
27
The Use of "QUAD Shot" in Anal Canal Squamous Cell Carcinoma: A Case Study With Review of the Literature. 61
30403973 2019
28
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier). 61
31118786 2019
29
Definitive chemoradiotherapy for anal canal cancer: single-center experience. 61
29992389 2018
30
Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03). 61
30172453 2018
31
Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal. 61
30662475 2018
32
Experimental and investigational drugs for the treatment of anal cancer. 61
30381968 2018
33
Corrigendum to: Squamous cell carcinoma of the anal canal: a review of the aetiology, presentation, staging, prognosis and methods available for treatment. 61
31040005 2018
34
So Now My Patient Has Squamous Cell Cancer: Diagnosis, Staging, and Treatment of Squamous Cell Carcinoma of the Anal Canal and Anal Margin. 61
30397394 2018
35
Intensity-modulated radiotherapy for synchronous cancer of the anal canal and cervix. 61
30197673 2018
36
Squamous cell carcinoma of the anal canal. 61
30497849 2018
37
Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes. 61
29907489 2018
38
Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 61
30006428 2018
39
Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. 61
30006430 2018
40
Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer. 61
27849650 2018
41
The impact of MRI sequence on tumour staging and gross tumour volume delineation in squamous cell carcinoma of the anal canal. 61
29134349 2018
42
Prognostic value of serum CYFRA 21-1 1 in patients with anal canal squamous cell carcinoma treated with radio(chemo)therapy. 61
29653564 2018
43
Management of Stage I Squamous Cell Carcinoma of the Anal Canal. 61
29049547 2018
44
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy. 61
29482779 2018
45
Synchronous Squamous Cell Carcinoma of the Anorectum and Proctosigmoid-a Case Report. 61
29581689 2018
46
[A Case of Anal Canal Squamous Cell Carcinoma Detected with Anal Stenosis Eight Years Following Resection for Rectal Adenocarcinoma]. 61
29362310 2018
47
The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. 61
29315288 2017
48
Radiation generates an abscopal response and complete resolution of metastatic squamous cell carcinoma of the anal canal: a case report. 61
29299375 2017
49
Management of early anal cancer: need for guidelines and standardisation. 61
29034437 2017
50
PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. 61
28557585 2017

Variations for Anal Canal Squamous Cell Carcinoma

Expression for Anal Canal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Anal Canal Squamous Cell Carcinoma.

Pathways for Anal Canal Squamous Cell Carcinoma

Pathways related to Anal Canal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.13 VEGFD PSENEN NCSTN MAPK8IP1 FLT1
2 12.25 VEGFD MAPK8IP1 FLT1
3
Show member pathways
11.47 PSENEN NCSTN
4
Show member pathways
11.19 PSENEN NCSTN
5 10.98 PSENEN NCSTN
6 10.52 PSENEN NCSTN
7 10.19 PSENEN NCSTN
8
Show member pathways
9.83 VEGFD FLT1

GO Terms for Anal Canal Squamous Cell Carcinoma

Cellular components related to Anal Canal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gamma-secretase complex GO:0070765 8.62 PSENEN NCSTN

Biological processes related to Anal Canal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 Notch signaling pathway GO:0007219 9.54 PSENEN NCSTN
2 ephrin receptor signaling pathway GO:0048013 9.52 PSENEN NCSTN
3 protein processing GO:0016485 9.51 PSENEN NCSTN
4 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.49 VEGFD FLT1
5 positive regulation of catalytic activity GO:0043085 9.48 PSENEN NCSTN
6 membrane protein ectodomain proteolysis GO:0006509 9.46 PSENEN NCSTN
7 membrane protein intracellular domain proteolysis GO:0031293 9.43 PSENEN NCSTN
8 vascular endothelial growth factor signaling pathway GO:0038084 9.4 VEGFD FLT1
9 amyloid precursor protein catabolic process GO:0042987 9.37 PSENEN NCSTN
10 positive regulation of endopeptidase activity GO:0010950 9.32 PSENEN NCSTN
11 amyloid precursor protein metabolic process GO:0042982 9.26 PSENEN NCSTN
12 amyloid-beta formation GO:0034205 9.16 PSENEN NCSTN
13 Notch receptor processing GO:0007220 8.96 PSENEN NCSTN
14 Notch receptor processing, ligand-dependent GO:0035333 8.62 PSENEN NCSTN

Sources for Anal Canal Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....